BCL2 and breast carcinoma: Dihydroartemisinin (DHA)‐loaded liposomes enhanced the circulation time of Epirubicin and improved its efficacy in different breast cancer cells by reducing Bcl‐2 activity, promoting Beclin‐1 release, and activating Bax.